En lile nyhed fra Neuro. Spaendende at se hvad der kommer af nyt fra dem i naermeste fremtid. If Troldmanden skulle det snart vaere tid for nyheder om fuld inrullering paa fase 3 forsoeg med Huntexil, en lille kurstrigger, maaske inden for faa dage.
Der er isaer fra troldmandens side kommet saa mange gode info. om Neurosearch, men i mange forskellige traade. Svaert at faa hurtigt overblik. Er det en ide med en Neurosearch traad efter Huntexil springet? Jeg forsoeger med denne her..
Neurosearch/CEO: Tesofensine strategiplan i H1 - bureau
24-03-2010 - 11:25
Anbefalinger: Ingen - Anbefal denne nyhed
Tip en ven om denne nyhed Tip en ven
Udskriv denne nyhed Udskriv
Neurosearch venter at komme med en strategiudmelding i første halvår 2010 om de videre planer for udviklingen af fedmemidlet tesofensine til behandling af svær overvægt. Det skriver nyhedsbureauet Reuters.
- Her i løbet af første halvår formodentlig, kommer vi med en strategiudmelding om, hvad vi gør, og hvad vi venter at etablere sammen med FDA (de amerikanske sundhedsmyndigheder, red.), som er den myndighed, vi primært diskuterer med, siger administrerende direktør Flemming Pedersen i et interview med Reuters.
Fase III programmerne for tesofensine, der består af fire store og meget dyre fase III studier, skal snart igangsættes.
En ting står dog fast: Neurosearch vil ikke gennemføre hele fase III programmet alene, og hvis det besluttes at påbegynde de fire studier samtidigt, så bliver det med en partner.
- Vi vil ikke starte et helt fase tre program selv, som det ser ud lige nu, det har vi ikke finansiering til. Og jeg mener også, at det vil flytte hele vores risikoprofil meget, hvis vi bare gik i gang med hele fase tre programmet med alle fire studier, siger Flemming Pedersen til nyhedsbureauet.
Han pointerer, at selskabet fortsat arbejder på at skaffe en partner til tesofensine - og at selskabet tidligere har været meget tæt på at lukke en aftale. Den afgørende faktor har været omstændigheder uden for Neurosearch' indflydelse, understreger Flemming Pedersen, der dog understreger, at selskabet fortsat er i tæt dialog med mulige partnere.
(RB-Børsen: Tlf: 33300335, E-mail: redaktion@rb-borsen.dk, www.rb-borsen.dk )
Der er isaer fra troldmandens side kommet saa mange gode info. om Neurosearch, men i mange forskellige traade. Svaert at faa hurtigt overblik. Er det en ide med en Neurosearch traad efter Huntexil springet? Jeg forsoeger med denne her..
Neurosearch/CEO: Tesofensine strategiplan i H1 - bureau
24-03-2010 - 11:25
Anbefalinger: Ingen - Anbefal denne nyhed
Tip en ven om denne nyhed Tip en ven
Udskriv denne nyhed Udskriv
Neurosearch venter at komme med en strategiudmelding i første halvår 2010 om de videre planer for udviklingen af fedmemidlet tesofensine til behandling af svær overvægt. Det skriver nyhedsbureauet Reuters.
- Her i løbet af første halvår formodentlig, kommer vi med en strategiudmelding om, hvad vi gør, og hvad vi venter at etablere sammen med FDA (de amerikanske sundhedsmyndigheder, red.), som er den myndighed, vi primært diskuterer med, siger administrerende direktør Flemming Pedersen i et interview med Reuters.
Fase III programmerne for tesofensine, der består af fire store og meget dyre fase III studier, skal snart igangsættes.
En ting står dog fast: Neurosearch vil ikke gennemføre hele fase III programmet alene, og hvis det besluttes at påbegynde de fire studier samtidigt, så bliver det med en partner.
- Vi vil ikke starte et helt fase tre program selv, som det ser ud lige nu, det har vi ikke finansiering til. Og jeg mener også, at det vil flytte hele vores risikoprofil meget, hvis vi bare gik i gang med hele fase tre programmet med alle fire studier, siger Flemming Pedersen til nyhedsbureauet.
Han pointerer, at selskabet fortsat arbejder på at skaffe en partner til tesofensine - og at selskabet tidligere har været meget tæt på at lukke en aftale. Den afgørende faktor har været omstændigheder uden for Neurosearch' indflydelse, understreger Flemming Pedersen, der dog understreger, at selskabet fortsat er i tæt dialog med mulige partnere.
(RB-Børsen: Tlf: 33300335, E-mail: redaktion@rb-borsen.dk, www.rb-borsen.dk )
24/3 2010 13:23 colombuss 0
27530 Nu er jeg ioevrigt ikke teknikker, mens syntes ca dette kursniveu maa have enorm stoette, hvis man ser paa 5 aars chart - ogsaa naevnt af Hjort - saa er dette et helt bemaerkelsesvaerdigt niveau. Min haab er at siden vi nu rider paa Huntexil boelgen, at ca. det nuvaerende kursniveau som i 5 aar har vaeret et kardinalpunkt, vil vaere bunden og afsaettet for fornyet fremgang. Vi faar se, isaer om vi undgaar generel nedgang i markedet, for saa kan det jo godt vaere at dette tekniske niveau ikke holder..Men FA maessigt er det et godt entry point. Men min finger er parat paa aftraekkeren hvis markedet ligepludselig vil ned..
24/3 2010 13:36 butterboy 027533 Ser ud til , at der stadig er liv i Tesofensine. Det er vel værdisat til 0 idag, så alt positivt nyt må give positivt på kursen.
Det bekræftes også, at man tidligere var meget tæt på en aftale, og at det var andre forhold, der gjorde, at det ikke blev til noget:
Han pointerer, at selskabet fortsat arbejder på at skaffe en partner til tesofensine - og at selskabet tidligere har været meget tæt på at lukke en aftale. Den afgørende faktor har været omstændigheder uden for Neurosearch' indflydelse, understreger Flemming Pedersen, der dog understreger, at selskabet fortsat er i tæt dialog med mulige partnere.
Det bekræftes også, at man tidligere var meget tæt på en aftale, og at det var andre forhold, der gjorde, at det ikke blev til noget:
Han pointerer, at selskabet fortsat arbejder på at skaffe en partner til tesofensine - og at selskabet tidligere har været meget tæt på at lukke en aftale. Den afgørende faktor har været omstændigheder uden for Neurosearch' indflydelse, understreger Flemming Pedersen, der dog understreger, at selskabet fortsat er i tæt dialog med mulige partnere.
24/3 2010 14:01 colombuss 027535 Ja en partnerskabsaftale vil vaere en stor kurstrigger. Eller hvis en af de oevrige stoffer i pipelinen ligepludselig kunne blive dokumenteret som i samme klasse som Huntexil, og det er slet ikke urealistisk, saa er der dobbelt op
24/3 2010 15:52 troldmanden 027542 Det er fint de vil melde ud i 1. halvår hvad deres strategi præcis er med Tesofensine. For det er noget uklart hvad der skal ske med dette stof ovenpå SCOUT studiet med Sibutramine.
Der er ingen tvivl om at HVIS de kan lande en aftale om stoffet så vil det være positivt for kursen. Men jeg tror det er mere end svært at lukke en aftale uden yderliger data.
Modsat så vil en nedlukning af projektet også straffe kursen selvom de fleste analytikere stort set ikke længer indregner projektet.
Mht Huntexil så tror jeg ikke en meddelelse om fuldt indrullering vil betyde noget for kursen. Det er nye data og/eller aftaler og/eller stoffer der starter ny fase der skal få kursen op.
Vh
T.
Der er ingen tvivl om at HVIS de kan lande en aftale om stoffet så vil det være positivt for kursen. Men jeg tror det er mere end svært at lukke en aftale uden yderliger data.
Modsat så vil en nedlukning af projektet også straffe kursen selvom de fleste analytikere stort set ikke længer indregner projektet.
Mht Huntexil så tror jeg ikke en meddelelse om fuldt indrullering vil betyde noget for kursen. Det er nye data og/eller aftaler og/eller stoffer der starter ny fase der skal få kursen op.
Vh
T.
7/4 2010 08:18 colombuss 027939 Neurosearch/Piper J: Dækning indledes med "overvægt"
07-04-2010 - 07:14
Anbefalinger: Ingen - Anbefal denne nyhed
Tip en ven om denne nyhed Tip en ven
Udskriv denne nyhed Udskriv
En ny analytiker melder sig på banen i Neurosearch, da Piper Jaffray indleder dækning med den stærke købsanbefaling "overvægt" og sætter kursmålet til 282 kr. Det viser data fra Bloomberg News. Aktien lukkede tirsdag i 168 kr.
Af 11 analytikere, der følger aktien på Bloomberg har 10 en købsanbefaling, mens en har en salgsanbefaling, viser data fra Bloomberg.
(RB-Børsen: Tlf: 33300335, E-mail: redaktion@rb-borsen.dk, www.rb-borsen.dk )
Ganske betryggende at laegge i Neurosearch i nuvaerende niveau
07-04-2010 - 07:14
Anbefalinger: Ingen - Anbefal denne nyhed
Tip en ven om denne nyhed Tip en ven
Udskriv denne nyhed Udskriv
En ny analytiker melder sig på banen i Neurosearch, da Piper Jaffray indleder dækning med den stærke købsanbefaling "overvægt" og sætter kursmålet til 282 kr. Det viser data fra Bloomberg News. Aktien lukkede tirsdag i 168 kr.
Af 11 analytikere, der følger aktien på Bloomberg har 10 en købsanbefaling, mens en har en salgsanbefaling, viser data fra Bloomberg.
(RB-Børsen: Tlf: 33300335, E-mail: redaktion@rb-borsen.dk, www.rb-borsen.dk )
Ganske betryggende at laegge i Neurosearch i nuvaerende niveau
7/4 2010 10:18 colombuss 027946 Piper Jaffray
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Piper Jaffray & Co. Piperjaffray.png
Type Public NYSE: PJC
Industry Financial Services
Founded Minneapolis, Minnesota (1895)
Headquarters Flag of the United States.svg Minneapolis, Minnesota
Key people Andrew S. Duff, Chairman and CEO
Website www.piperjaffray.com
Piper Jaffray & Co. (NYSE: PJC), often shortened to just Piper Jaffray or PiperJaffray, is a U.S. middle-market investment banking firm based in Minneapolis, Minnesota, and sells financial advice, investment products, and transaction execution within targeted sectors of the financial services marketplace. Through its principal subsidiary, Piper Jaffray & Co., the Company targets corporations, government, non-profit entities, institutional investors, and the financial advisory needs of private individuals.
Contents
[hide]
* 1 History
* 2 Operations
* 3 Regulator fines
* 4 Notes
* 5 External links
* 6 Additional Resources
[edit] History
Piper Jaffray traces its roots to 1895 when George Lane established George B. Lane, Commercial Paper and Collateral Loans & Co., a commercial paper brokerage, in Minneapolis. In 1913, Piper, Jaffray Co. was established as another commercial paper business by H.C. Piper Sr. and C.P. Jaffray. In 1917, George B. Lane & Co. merged with Piper, Jaffray & Co. to form Lane, Piper & Jaffray.
The firm first obtained a seat on the New York Stock Exchange in 1931 with the acquisition of Hopwood & Company, which had been devastated by the stock market crash. In 1971, Piper first offered stock to the public and became a publicly held corporation known as Piper, Jaffray & Hopwood Incorporated. Later, in 1986, Piper's common stock began trading on the NASDAQ under the ticker symbol PIPR. In 1997, the firm was acquired by Minneapolis based U.S. Bancorp for $730 million in cash. From 1999 to 2003, the firm was known as U.S. Bancorp Piper Jaffray. In 2003 U.S. Bancorp spun off Piper Jaffray in a stock dividend to its shareholders, and today the company is traded independently under the symbol PJC. In 2006, the company sold its brokerage business to Zurich based UBS for $510 million in cash. The business had approximately 800 brokers at that time.
Piper Jaffray now has 28 offices, with over 1,000 employees serving its capital markets clients.
[edit] Operations
The Capital Markets division includes investment banking, institutional sales and trading, and securities research. Focus areas include health care, consumer, financial institutions and technology. The firm is the largest underwriter of municipal bonds in its headquarters state of Minnesota. Piper Jaffray is especially noted for its underwriting of middle market IPOs, convertible securities, and private placements.[citation needed]
In July 2007, Piper Jaffray agreed to acquire Goldbond Capital Holdings Limited, a leading Hong Kong-based investment bank, for approximately $50 million, funding the deal with 90% cash and 10% stock.[1] The move aimed to give Piper Jaffray full capital-raising capability, especially for initial public offerings by Chinese companies that want to list on the Hong Kong Stock Exchange. Founded in 2003 by chairman and CEO Alex Ko who was previously head of corporate finance at BNP Paribas Peregrine Capital in Asia, Goldbond focused primarily on raising capital for and providing financial advisory services to HKEX-listed companies. It offered corporate finance, sales and trading, equity capital markets and research capabilities, and employed 70 people in HK as well as a small staff in Shanghai.
Piper Jaffray is putting a lot of emphasis on China, and it already has an office in Shanghai. In March 2007, it held its annual China growth conference, now in its fourth year, which looked at a broad range of growth sectors including the internet, technology, education, consumer, and solar power.
Piper Jaffray has been active in China since 2003 and is a leading equity underwriter for China issuers listing on U.S. exchanges, with 23 completed deals from January 1, 2003 to June 2007. It has, for example, in February 2007 helped underwrite the $258.8 million initial public offering of JA Solar Holdings Co. in Ningjin, China, [2] and in August 2005?the $123.4 million IPO of Baidu.com, often called the Google of China.[3]
Piper Jaffray will now have offices in the world's three most important financial centers?New York, London, and Hong Kong.
[edit] Regulator fines
In 2002, Piper Jaffray was fined $25 million by state and federal regulators to settle charges that it provided biased stock ratings. Other firms, such as JP Morgan and Goldman Sachs were also fined for similar reasons. The firm agreed to make structural changes relating to its research and investment banking program in order to restore confidence in its business.[4]
[edit] Notes
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Piper Jaffray & Co. Piperjaffray.png
Type Public NYSE: PJC
Industry Financial Services
Founded Minneapolis, Minnesota (1895)
Headquarters Flag of the United States.svg Minneapolis, Minnesota
Key people Andrew S. Duff, Chairman and CEO
Website www.piperjaffray.com
Piper Jaffray & Co. (NYSE: PJC), often shortened to just Piper Jaffray or PiperJaffray, is a U.S. middle-market investment banking firm based in Minneapolis, Minnesota, and sells financial advice, investment products, and transaction execution within targeted sectors of the financial services marketplace. Through its principal subsidiary, Piper Jaffray & Co., the Company targets corporations, government, non-profit entities, institutional investors, and the financial advisory needs of private individuals.
Contents
[hide]
* 1 History
* 2 Operations
* 3 Regulator fines
* 4 Notes
* 5 External links
* 6 Additional Resources
[edit] History
Piper Jaffray traces its roots to 1895 when George Lane established George B. Lane, Commercial Paper and Collateral Loans & Co., a commercial paper brokerage, in Minneapolis. In 1913, Piper, Jaffray Co. was established as another commercial paper business by H.C. Piper Sr. and C.P. Jaffray. In 1917, George B. Lane & Co. merged with Piper, Jaffray & Co. to form Lane, Piper & Jaffray.
The firm first obtained a seat on the New York Stock Exchange in 1931 with the acquisition of Hopwood & Company, which had been devastated by the stock market crash. In 1971, Piper first offered stock to the public and became a publicly held corporation known as Piper, Jaffray & Hopwood Incorporated. Later, in 1986, Piper's common stock began trading on the NASDAQ under the ticker symbol PIPR. In 1997, the firm was acquired by Minneapolis based U.S. Bancorp for $730 million in cash. From 1999 to 2003, the firm was known as U.S. Bancorp Piper Jaffray. In 2003 U.S. Bancorp spun off Piper Jaffray in a stock dividend to its shareholders, and today the company is traded independently under the symbol PJC. In 2006, the company sold its brokerage business to Zurich based UBS for $510 million in cash. The business had approximately 800 brokers at that time.
Piper Jaffray now has 28 offices, with over 1,000 employees serving its capital markets clients.
[edit] Operations
The Capital Markets division includes investment banking, institutional sales and trading, and securities research. Focus areas include health care, consumer, financial institutions and technology. The firm is the largest underwriter of municipal bonds in its headquarters state of Minnesota. Piper Jaffray is especially noted for its underwriting of middle market IPOs, convertible securities, and private placements.[citation needed]
In July 2007, Piper Jaffray agreed to acquire Goldbond Capital Holdings Limited, a leading Hong Kong-based investment bank, for approximately $50 million, funding the deal with 90% cash and 10% stock.[1] The move aimed to give Piper Jaffray full capital-raising capability, especially for initial public offerings by Chinese companies that want to list on the Hong Kong Stock Exchange. Founded in 2003 by chairman and CEO Alex Ko who was previously head of corporate finance at BNP Paribas Peregrine Capital in Asia, Goldbond focused primarily on raising capital for and providing financial advisory services to HKEX-listed companies. It offered corporate finance, sales and trading, equity capital markets and research capabilities, and employed 70 people in HK as well as a small staff in Shanghai.
Piper Jaffray is putting a lot of emphasis on China, and it already has an office in Shanghai. In March 2007, it held its annual China growth conference, now in its fourth year, which looked at a broad range of growth sectors including the internet, technology, education, consumer, and solar power.
Piper Jaffray has been active in China since 2003 and is a leading equity underwriter for China issuers listing on U.S. exchanges, with 23 completed deals from January 1, 2003 to June 2007. It has, for example, in February 2007 helped underwrite the $258.8 million initial public offering of JA Solar Holdings Co. in Ningjin, China, [2] and in August 2005?the $123.4 million IPO of Baidu.com, often called the Google of China.[3]
Piper Jaffray will now have offices in the world's three most important financial centers?New York, London, and Hong Kong.
[edit] Regulator fines
In 2002, Piper Jaffray was fined $25 million by state and federal regulators to settle charges that it provided biased stock ratings. Other firms, such as JP Morgan and Goldman Sachs were also fined for similar reasons. The firm agreed to make structural changes relating to its research and investment banking program in order to restore confidence in its business.[4]
[edit] Notes
15/4 2010 14:29 Darvin 028214 I går (måske før - men der læste jeg det 
var der nyt fra en konkurrent til Tesofensine.
Som det fremgår regner de med godkendelse.
Der er altså fuldt ud liv i markedet for fedmemedicin.
Positivt for Neurosearch ?
Weight Loss Drug Contrave Not as Effective as Previously Reported, Says Drug Manufacturer
April 14, 2010, 09:04 am
Contrave, a new anti-obesity drug awaiting U.S. Food and Drug Administration (FDA) approval, may not be as effective as previously proven during drug trials, according to Orexigen Therapeutics Inc., the drug?s manufacturer.
Orexigen initially reported that 56.3 percent of patients in clinical trials lost 5 percent or more of their body weight after 56 weeks. On Tuesday, the drug maker reduced that statistic to 50.5 percent reporting a 5 percent or more weight loss.
Additionally, Orexigen reported that 32.9 percent of clinical trial patients lost 10 percent or more of their body weight. That number was also modified to 28.3 percent.
Contrave is a combination of the antidepressant bupropion (Wellbutrin) and the anti-addiction medication naltrexone, commonly prescribed to treat alcoholism. The combination works to stimulate neurons in the brain, reducing food intake, increasing metabolism, and blocking hormones that may thwart the body?s ability to continue losing weight.
The reporting mishap was attributed to a clerical error, said Michael Narachi, Orexigen?s chief executive.
?It?s odd that we didn?t catch it, but it doesn?t materially change our story,? he said.
Orexigen is currently waiting to receive confirmation from the FDA that their Contrave application is complete and ready for review.
Narachi said the changes to Contrave?s application are unlikely to affect drug approval time, and even with the adjustments, Contrave?s results still reached the goals the company had set to indicate clinically significant weight loss.
Additional information about drugs, drug side effects, and FDA alerts may be found on DrugWatch.com.
var der nyt fra en konkurrent til Tesofensine.Som det fremgår regner de med godkendelse.
Der er altså fuldt ud liv i markedet for fedmemedicin.
Positivt for Neurosearch ?
Weight Loss Drug Contrave Not as Effective as Previously Reported, Says Drug Manufacturer
April 14, 2010, 09:04 am
Contrave, a new anti-obesity drug awaiting U.S. Food and Drug Administration (FDA) approval, may not be as effective as previously proven during drug trials, according to Orexigen Therapeutics Inc., the drug?s manufacturer.
Orexigen initially reported that 56.3 percent of patients in clinical trials lost 5 percent or more of their body weight after 56 weeks. On Tuesday, the drug maker reduced that statistic to 50.5 percent reporting a 5 percent or more weight loss.
Additionally, Orexigen reported that 32.9 percent of clinical trial patients lost 10 percent or more of their body weight. That number was also modified to 28.3 percent.
Contrave is a combination of the antidepressant bupropion (Wellbutrin) and the anti-addiction medication naltrexone, commonly prescribed to treat alcoholism. The combination works to stimulate neurons in the brain, reducing food intake, increasing metabolism, and blocking hormones that may thwart the body?s ability to continue losing weight.
The reporting mishap was attributed to a clerical error, said Michael Narachi, Orexigen?s chief executive.
?It?s odd that we didn?t catch it, but it doesn?t materially change our story,? he said.
Orexigen is currently waiting to receive confirmation from the FDA that their Contrave application is complete and ready for review.
Narachi said the changes to Contrave?s application are unlikely to affect drug approval time, and even with the adjustments, Contrave?s results still reached the goals the company had set to indicate clinically significant weight loss.
Additional information about drugs, drug side effects, and FDA alerts may be found on DrugWatch.com.
